Home / Resource Library / REAL-WORLD EFFECTIVENESS AND SAFETY OUTCOMES AMONG KEY SUBGROUPS OF SECOND-LINE (2L) AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL)

REAL-WORLD EFFECTIVENESS AND SAFETY OUTCOMES AMONG KEY SUBGROUPS OF SECOND-LINE (2L) AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL)

EHA 2025

Membership Organisation

Healthcare Professional

Affected by Lymphoma

Researcher or Advocate

REAL-WORLD EFFECTIVENESS AND SAFETY OUTCOMES AMONG KEY SUBGROUPS OF SECOND-LINE (2L) AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL)